ストックスクリーナーアプリを入手
0.8999
7.46%
-0.0725
アフターアワーズ：
.92
0.0201
+2.23%
Pliant Therapeutics Inc (PLRX) 最新ニュース
David Raben receives a 575,000-share option at $1.05 per share from Pliant Therapeutics (PLRX). - Stock Titan
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - Investing News Network
Pliant Therapeutics names David Raben as chief medical officer By Investing.com - Investing.com Nigeria
Pliant Therapeutics names David Raben as chief medical officer - Investing.com
Pliant Therapeutics names David Raben as chief medical officer By Investing.com - Investing.com India
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer - GlobeNewswire
Price to earnings forward of Pliant Therapeutics, Inc. – DUS:9PT - TradingView
Pliant (PLRX) Watch: Finishes 1.74% Up at $1.17 at the Close; Technical View: the $1.11 to $1.23 Range Remains in Focus in the Available RecordUnusual Put Volume - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX) - The Globe and Mail
Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation - Simply Wall Street
symbol__ Stock Quote Price and Forecast - CNN
Why is Pliant Therapeutics stock climbing today? - Investing.com
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com India
Pliant Therapeutics (PLRX) Gains FDA Fast Track for PLN-101095 A - GuruFocus
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Why is Pliant Therapeutics stock climbing today? By Investing.com - Investing.com UK
Pliant Therapeutics receives FDA fast track for cancer drug By Investing.com - Investing.com Canada
Pliant Therapeutics receives FDA fast track for cancer drug - Investing.com
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - The Manila Times
Pliant Therapeutics Receives FDA Fast Track Designation for - GlobeNewswire
J.P. Morgan Maintains Pliant Therapeutics(PLRX.US) With Sell Rating - Moomoo
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors - markets.businessinsider.com
Pliant Therapeutics (PLRX) Advances Clinical Program Amidst Chal - GuruFocus
Monaco Asset Management SAM Purchases Shares of 1,938,747 Pliant Therapeutics, Inc. $PLRX - MarketBeat
Pliant Therapeutics Inc (FRA:9PT) Stock Price, Trades & News - GuruFocus
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneValue Stock Ideas - vinanet.vn
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneMutual Fund Flow - dars.gov.et
Pliant Therapeutics (PLRX) Slips to $1.07, Testing Critical Support ZoneLow Volume Node - dars.gov.et
Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell - MarketBeat
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan
Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding - Stock Titan
Price performance - Yahoo Finance Australia
CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - Moomoo
RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
PLRX (Pliant Therapeutics) 12-1 Month Momentum % : -30.79% (As of Aug. 17, 2026) - GuruFocus
Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs - scanx.trade
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Canada
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Pliant Therapeutics (PLRX) halves quarterly loss and reports $159.6M in cash reserves - Stock Titan
BRIEF-Pliant Therapeutics Q2 Net Income USD -22.371 Million - TradingView
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - markets.businessinsider.com
Pliant Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Fibrosis Pipeline AdvancesMargin Improvement Report - vinanet.vn
Pliant Therapeutics Inc (PLRX) Stock News Today - TradingKey
4.22%
大文字化:
|
ボリューム (24 時間):